Medicare AdvantagePrior AuthMedium impact
Reyvow™ (lasmiditan) (Revised)
Humana·Neurology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2024
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Reyvow (lasmiditan) for acute migraine treatment, with a new requirement that patients must have previous treatment, intolerance, or contraindication to Ubrelvy before approval. This policy is effective January 1, 2024 with approval duration for the plan year.
Action Required
Immediately: Billing team must update prior authorization workflows for Reyvow (lasmiditan) prescriptions for Humana Medicare Advantage patients. Providers must document that patients have had previous treatment, intolerance, or contraindication to Ubrelvy before prescribing Reyvow. Update EMR templates to include this requirement. Claims for Reyvow without prior authorization will be denied.